Abstract
Cognitive event-related potentials (ERPs) have been used as a marker of cognitive function in patients with psychiatric and neurological disorders. In particular, the P300 potential has been widely utilized to study dementia and aging, because the P300 ERP component is easily observed and reflects attention and memory processing. However, the relationship between parameters of the P300 potential and the severity or type of cognitive impairment in patients with Alzheimers disease (AD) remains controversial. Because specific and effective anti-dementia treatments have recently become available for AD, more useful information is needed about the clinical aspects of this disease, including methods of making an accurate and early diagnosis, differentiation from vascular dementia and other degenerative dementias, assessment of severity, assessment of disease progression, evaluation of the response to treatment, and prediction of the prognosis. This mini-review described new discoveries on recent clinical application of ERPs in AD with respect to the above-mentioned areas. Although the definition of normal ERP values and the most appropriate method of ERP recording in AD patients have not been well defined, recent findings suggest that ERP analysis may be a clinically useful, inexpensive, noninvasive, and reliable method of assessing AD.
Keywords: Cognitive event-related potentials, P300, Alzheimers disease
Current Alzheimer Research
Title: Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Volume: 1 Issue: 1
Author(s): Eiichi Katada, Koichi Sato, Kosei Ojika and Ryuzo Ueda
Affiliation:
Keywords: Cognitive event-related potentials, P300, Alzheimers disease
Abstract: Cognitive event-related potentials (ERPs) have been used as a marker of cognitive function in patients with psychiatric and neurological disorders. In particular, the P300 potential has been widely utilized to study dementia and aging, because the P300 ERP component is easily observed and reflects attention and memory processing. However, the relationship between parameters of the P300 potential and the severity or type of cognitive impairment in patients with Alzheimers disease (AD) remains controversial. Because specific and effective anti-dementia treatments have recently become available for AD, more useful information is needed about the clinical aspects of this disease, including methods of making an accurate and early diagnosis, differentiation from vascular dementia and other degenerative dementias, assessment of severity, assessment of disease progression, evaluation of the response to treatment, and prediction of the prognosis. This mini-review described new discoveries on recent clinical application of ERPs in AD with respect to the above-mentioned areas. Although the definition of normal ERP values and the most appropriate method of ERP recording in AD patients have not been well defined, recent findings suggest that ERP analysis may be a clinically useful, inexpensive, noninvasive, and reliable method of assessing AD.
Export Options
About this article
Cite this article as:
Katada Eiichi, Sato Koichi, Ojika Kosei and Ueda Ryuzo, Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease, Current Alzheimer Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567205043480609
DOI https://dx.doi.org/10.2174/1567205043480609 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer’s Disease
Current Alzheimer Research Genes and Hypertension
Current Pharmaceutical Design Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets The Concept of Phenoptosis and its Usefulness for Controlling Aging
Current Aging Science Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Computational Approach to Finding RNA Tertiary Motifs in Genomic Sequences: A Case Study
Recent Patents on DNA & Gene Sequences Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research Is Alzheimers Disease a Myth? When is Disease a Disease?
Current Alzheimer Research Editorial (Thematic Issue: Neuroglia in Alzheimer’s Disease: From Cohort to Contestant in the Disease Progression and its Therapy)
Current Alzheimer Research Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design Subject Index To Volume 2
Current Hypertension Reviews Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Current Alzheimer Research Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science Pharmacotherapy and the Psychobiological Model of Personality: Implications for DSM-5
Current Psychopharmacology